Fidelity SPDR Advertisement
Home > Boards > US OTC > Biotechs >

Nuvilex, Inc. (NVLX)

Add NVLX Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator bulldurham, Peacefulwendy, PetePham, Calculated-Risk
Search This Board:
Last Post: 10/31/2014 5:03:32 PM - Followers: 493 - Board type: Free - Posts Today: 0


ThaiTECT ???????? 14 - Drug Development Part I : International Experiences

Nuvilex/Austrianova declared the winner of the 2014 Best Innovation Award

Encapsulation of Insulin Producing Cells for Diabetes Treatment Using 
Alginate and Cellulose Sulphate as Bioencapsulation Polymers

NUVILEX (NVLX)- The Next Great Biotech Story (VIDEO)


Nuvilex Company Address
   Nuvilex, Inc.
   Meadows Corporate Park I
   12510 Prosperity Dr., Suite #310
   Silver Spring, MD 20904-1643
   Phone:  (877) 958-7616 , (917) 595-2850
   Fax: (917) 595-2851

Shares Outstanding:
709,256,214 a/o Aug 26, 2014

Authorized Shares:
1,490,000,000 a/o Aug 26, 2014

529,206,849 a/o Aug 26, 2014

Short Selling Data
Short Interest: 8,450,144 a/o Aug 29, 2014

For more updated information please visit:

Transfer Agent:
Signature  Stock Transfer Inc. Plano TX  Ph # 972-612-4120

Investor Relations

Clare Matschullat 
Blueprint Life Science Group 
Telephone: 415.375.3340 Ext. 106 


All News Releases:

All Information about Nuvilex:

What is Cell-in-a-Box®?

The Cell-in-a-Box® technology, developed by Austrianova, is a means to protect, isolate, storeand transport living cells. The proprietary technology can be used for a variety of purposes.
In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients. 
In biotechnology, the Cell-in-a-Box® technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost. 
The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool. 
The company’s proprietary cell packaging material, Gel8, used for the Cell-in-a-Box® technology, is derived from a naturally occurring material and is thus harmless to the environment, biologically inert and has been shown to be safe in humans. 

Nuvilex is a biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology, called Cell-in-a-Box(TM). This unique technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. The Company's treatment for pancreatic cancer involves the use of the widely used anticancer prodrug, ifosfamide, together with encapsulated live cells that convert ifosfamide into its active or "cancer-killing" form. Nuvilex's subsidiary, Medical Marijuana Sciences, Inc., is dedicated to the development of cancer treatments based upon chemical constituents of marijuana known as cannabinoids. To do so, it will examine ways to exploit the benefits of Cell-in-a-Box(TM) technology in optimizing the anticancer effectiveness of cannabinoids against cancers while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides Medical Marijuana Sciences a unique opportunity to develop "green" approaches to fighting deadly cancers, such as those of the pancreas, brain, breast and prostate, that affect hundreds of thousands of individuals worldwide.

Nuvilex has acquired worldwide exclusive rights to the cellulose-based live cell-encapsulation technology, also known as Cell-in-a-Box™, and described above, from SG Austria Pte. Ltd. for the development of treatments for any and all types of cancer. The rights to use the cancer drug-activating cells that will be part of Nuvilex’s treatment for advanced pancreatic cancer (see Pancreatic Cancer section of this website) were also acquired. The acquisition of rights to use the Cell-in-a-Box™ technology for the development of treatments for insulin-dependent diabetes has recently been completed.



Austria Nova Demonstration Video


SMMG Radio Interview with COO Dr. Crabtree ~ 2013

Shareholder Update with CEO & COO via SMMG Interview ~ July 2014

The proprietary technology can be used for a variety of purposes.

In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients.

In biotechnology, the Cell-in-a-Box™ technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost.

The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool.


Medical Marijuana Sciences





Management Team:

Kenneth L. Waggoner, Chief Executive Officer and President:

Kenneth L. Waggoner has almost four decades of experience in management, business, operations and law.  Mr. Waggoner started his career as an attorney in private practice. Notably he was a senior partner with Brobeck, Phleger and Harrison, named one of the top two law firms worldwide that provide services to biotechnology clients including Chiron, Amgen, Biogen Idec, Sangamo, Ligand, DepoTech and many others.  He was the Managing Partner of Brobeck’s Los Angeles office.  Mr. Waggoner was also a member of the Executive Committee for almost ten years and on the Policy Committee for numerous years managing Brobeck’s worldwide operations with annual revenues in excess of $750,000,000.  While at Brobeck, Mr. Waggoner was the Co-Chairman of Brobeck’s world-wide Environmental Law Group.

Further highlights of Mr. Waggoner’s career include leadership and legal positions with several start-up companies during the last several years as well as working with Fortune 500 companies most of his professional career.  During his tenure with Chevron, Mr. Waggoner served as the Vice President and General Counsel of its Global Downstream operations where he was responsible for the overall management of legal services to the North American, Latin American, Europe and Asian Products Companies.  At Chevron he led a successful restructuring of the company’s international Legal Department following Chevron’s acquisition of Texaco.

Mr. Waggoner received his Juris Doctorate. with honors in 1973 from Loyola University School of Law in Los Angeles.


Gerald W. Crabtree, Ph.D. – Chief Operating Officer and Director:

Dr. Crabtree is the Company’s Chief Operating Officer.  Since 1985, Dr. Crabtree has been involved with various biopharmaceutical companies where he has alternatively supervised and coordinated the development of multiple drug candidates, prepared clinical protocols, investigator brochures, monographs, research and review articles and served as project manager for development of major oncologic agents.  He is a Member of the American Society of Clinical Oncology and also is a past member of research grant review committees for the National Institute of Health and the American Cancer Society.  Dr. Crabtree established and directed, from inception, a department that monitored and coordinated the development of oncologic and immunologic drugs from initial discovery through regulatory approval in a major pharmaceutical company and served as project manager for the development of the anticancer agent, Taxol®.

Dr. Crabtree received his Ph.D. in Biochemistry from the University of Alberta, Edmonton, Alberta, Canada and has published over 80 articles in peer-reviewed journals.  He is a National Cancer Institute of Canada Research Fellow.  In addition, he served as Department Head of Molecular Pharmacology for the Nucleic Acid Research Institute, and prior to that as Associate Professor of Medicine with the Roger Williams Cancer Center at Brown University.  Dr. Crabtree has also served as Director of Project Planning and Management (Oncology/Immunology) at Bristol-Myers Squibb and as Vice-President of Research and Development at ETEX Corporation.  Most recently, Dr. Crabtree served as Interim CEO of PhytoCeutica, Inc., where he assisted in preparation and review of FDA documents, clinical study protocols, investment acquisitions and contracts and business plans.

Walter H. Gunzburg – Chief Scientific Officer:

Prof. Walter H. Gunzburg is the co-founder, Chairman of the Board and Chief Technical Officer of Austrianova. As well as being a full Professor of Virology at the University of Vienna since 1996, he has had many years of experience in the biotech industry. He was a scientific advisor to the international vaccine company, Bavarian Nordic, from 1994-2001 and was involved in their IPO. He has also been an scientific advisor to the German biotech companies, Paktis and Liponova, as well as the U.S. biotech company, Tocagen Inc., all of which developed/are developing advanced medicinal treatments for cancer. He was also the Director of the Christian Doppler Laboratory for Gene Therapeutic Vector Development from 2003-2011. Currently, he is a board member of ViruSure, a virus and prion testing company located in Vienna that he cofounded.

Prof. Gunzburg has been actively involved in European ethics and regulatory affairs in the fields of cell and gene therapy as well as xenotransplantation for many years. He was a member of the German Medical Association's Central Commission for Somatic Gene Therapy. He has also interacted with a number of regulatory agencies including the US FDA, EMA, TGA, HSA and Thai-FDA and was on the review panel for the Paul Ehrlich Institute, Langen, Germany. Prof. Gunzburg continues to be an active researcher and has published more than 130 peer-reviewed publications in international scientific and medical journals such as NatureThe Lancet,Proceedings of the National Academy of Sciences USA and Cancer Research as well as co-authoring the first German language textbook on gene therapy. He is also a member of the editorial board of a number of international cell and gene therapy journals including Trends in Molecular Medicine, and continues to be an active reviewer for many top tier journals as well as grant funding agencies.

Dr. Matthias Lohr as Chairman of Scientific Advisory Board:

Matthias Löhr was appointed professor of gastroenterology & hepatology at Karolinska Institutet in 2007, incoming from the Univ. Heidelberg/dkfz. From the times of his MD thesis through PhD and lateron, he concentrated on several aspects of the pancreas, both in clinical medicine, translational and basic sciences. He is heading the Pancreas Research Team at Gastrocentrum and leading the KICancer Diagnose-related network for HPB tumors. For hte European Gastroenterologists (UEG), he is sitting in several committees at the EU in Brussels. He is also leading the Pancreas 2000 program, an educational program for future pancreatologists in Europe.

Stock Chart
Company Info
Recent News
Filings and Disclosure
Short Sales
Insider Disclosure
Research Reports
Historical Prices
Interactive Chart
Basic Chart
Basic Tech. Analysis
Press Releases
Company Profile
Key Statistics
Major Holders
Insider Transactions
Insider Roster
Income Statement
Balance Sheet
Cash Flow
Market Watch
OTC Short Report




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
NVLX News: Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) 10/29/2014 08:20:03 AM
NVLX News: Notice of Effectiveness (effect) 10/29/2014 06:01:20 AM
NVLX News: Securities Registration Statement (simplified Form) (s-3/a) 10/24/2014 05:01:34 PM
NVLX News: Nuvilex Contracts with University of Veterinary Medicine in Vienna to Conduct Preclinical Studies to Develop Diabetes Treatment 10/20/2014 09:00:00 AM
NVLX News: Securities Registration Statement (simplified Form) (s-3) 10/17/2014 04:00:54 PM
#27475  Sticky Note Nuvilex, Inc. Engaged in "Cutting Edge" Cannabis Preclinical bulldurham 10/29/14 08:52:42 AM
#27216  Sticky Note PR OUT...Nuvilex Contracts With University of Veterinary Medicine bulldurham 10/20/14 09:04:54 AM
#27185  Sticky Note Nuvilex Applies to FDA for Orphan Drug Designation PetePham 10/17/14 09:58:02 PM
#18112  Sticky Note EVERYONE please keep your posts on-topic. The topic IH Geek [Dave] 03/14/14 12:28:20 PM
#27570   I agree with you completely. The next trading rudygerner 10/31/14 05:03:32 PM
#27569   NOW is the time to accumulate NVLX...and it bulldurham 10/31/14 04:18:20 PM
#27568   Please disregard that message. I meant to say young_wolf_350 10/31/14 04:15:25 PM
#27564   What's with the 3 quick big spikes in walterm32 10/31/14 03:16:00 PM
#27559   Could waiting until pancreatic cancer awareness month to young_wolf_350 10/31/14 08:33:29 AM
#27558   Blessings all you Longs out there. The Promised Land 10/31/14 08:14:14 AM
#27555   Good point Rudy. Jimmy Joe 10/31/14 12:01:35 AM
#27554   Agree with Bull and jackpam. This is a Jimmy Joe 10/30/14 11:00:37 PM
#27553   jackpam I don't know what the tax structure Jimmy Joe 10/30/14 10:52:33 PM
#27552   Good time to accumulate was when it was jackpam 10/30/14 10:20:05 PM
#27550   Things just keep getting better and better for Doughboy37 10/30/14 09:25:55 PM
#27549   I do not understand why everyone keeps saying LuCo 10/30/14 09:18:04 PM
#27548   The pre-clinicals are taking a good, long time rudygerner 10/30/14 08:34:46 PM
#27547   I think you are right on, bull. Peacefulwendy 10/30/14 07:12:37 PM
#27546   That too. I simply was responding to pjbwheeeze 10/30/14 05:44:28 PM
#27545   do you have any idea when FDA will approve. cattop 10/30/14 04:39:15 PM
#27544   If the delivery system is successful there will thenewmixer 10/30/14 03:40:18 PM
#27542   I agree Pete. They still have to repeat Jimmy Joe 10/30/14 03:17:06 PM
#27540   If the delivery system is successful, the stock pjbwheeeze 10/30/14 02:01:31 PM
#27539   If there were to be a reverse spit thenewmixer 10/30/14 01:33:46 PM
#27537   I am with you Bull. I am beginning avobill 10/30/14 01:20:09 PM
#27536   Great buy and accumulate for more shares. It PetePham 10/30/14 01:19:52 PM
#27535   This NVLX is a buy and hold type bulldurham 10/30/14 01:14:19 PM
#27533   Cell_in_a_Box treated mice are living longer than expected bulldurham 10/30/14 01:06:42 PM
#27532   Headed back to the TEENS? Alydyr 10/30/14 12:46:26 PM
#27531   Everything they have been saying since KW took urup 10/30/14 12:41:53 PM
#27530   and how do you know it is coming jackpam 10/30/14 12:37:38 PM
#27529   TD2/Von Hoff Pre-Clinical Update coming some time soon! Setay 10/30/14 12:27:34 PM
#27527   Encaptra En250 is approx. 3x5cm device which is surgercially urup 10/30/14 12:25:19 PM
#27526  Restored Pump-n-Dump in play here at NVLX Alydyr 10/30/14 11:41:16 AM
#27525   I wish I had a dime every time thenewmixer 10/30/14 11:34:49 AM
#27524   I can answer that with one thing...200dma... bulldurham 10/30/14 11:25:12 AM
#27523   What are the differentiators between our product and pjbwheeeze 10/30/14 10:46:19 AM
#27520   Viacyte Not ours, compare the two. Ours IMO, is better. urup 10/30/14 09:12:41 AM
#27519   Whoever posted the REverse split GARBAGE is misinforming hispeed 10/30/14 09:05:19 AM
#27518   A friend of mine that I grew up pingbag 10/30/14 09:05:02 AM
#27517   no one said its was going to happen thenewmixer 10/30/14 08:53:08 AM
#27514   Introducing Nuvilex for Potential New Investors: Setay 10/30/14 08:10:46 AM
#27513   Mathematically that is accurate. However, you are looking Gmc2020 10/30/14 07:45:02 AM
#27512   How is it ridiculous? Lets say you have young_wolf_350 10/30/14 07:12:13 AM
#27511   Blessings and Good morning Nuvilex Investors. The Promised Land 10/30/14 06:57:54 AM
#27510   That's just ridiculous ... Eps is would increase Gmc2020 10/30/14 01:38:06 AM
#27509   Cell-in-a-Box® New PetePham 10/30/14 12:54:32 AM
#27507   The live cell encapsulation that we are working PetePham 10/29/14 10:39:23 PM
#27505   just saying nvlx is along way from being thenewmixer 10/29/14 05:00:18 PM
#27504   Right. Less shares means less of a return young_wolf_350 10/29/14 04:52:03 PM
#27503   you will have the same value just less shares thenewmixer 10/29/14 04:50:38 PM
#27502   and sometime you have to tell someone that thenewmixer 10/29/14 04:48:27 PM
#27501   Geez not one is investing in nvlx now thenewmixer 10/29/14 04:46:36 PM
#27500   It would also mean less of a return young_wolf_350 10/29/14 03:56:20 PM